Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Abi Berger BMJ
Malaria can be prevented. Unfortunately, travellers to
areas where malaria is common often put themselves at risk of
contracting the disease by ignoring the key steps in malaria
prevention. The steps are simple but if ignored can result in
unnecessary morbidity and, in some cases, death. The key steps to
protect against malaria are:
A B C D The number of cases of malaria imported into the United Kingdom is
rising (figure), and over half of them are potentially fatal
(falciparum malaria). The risks from the disease must be compared
sensibly with the risks associated with the drugs recommended for
prophylaxis. Obtaining true figures for the incidence of side effects
is difficult and in some cases controversial. This is partly because as
doctors become more aware of potential side effects, more side effects
are looked for and then reported. Also, it is virtually impossible to
perform anything other than observational studies on side effects
because sending people to malarious areas with placebo drugs only would
be unethical.
Two other factors make it difficult to determine the incidence of side
effects. Firstly, of the huge number of people taking antimalaria drugs
some will get concurrent symptoms and diseases while abroad, and
deciding whether to attribute these to the antimalaria drugs is
difficult. Secondly, attributing subjective side effects to drugs is a
common phenomenon, even for placebo drugs.
With short acting drugs (for example, proguanil, which is taken daily)
side effects usually occur after just one dose. With longer acting
drugs (for example, mefloquine, which is taken weekly), side effects
may not become apparent until after the third dose.
Two large studies have reported the incidence of side effects of
mefloquine compared with chloroquine and proguanil. Barrett et al found
that both regimens had similar rates of any side effect occurring
(40%), although most side effects were trivial.1 About
0.7% of travellers taking mefloquine reported severe, disabling neuropsychiatric symptoms compared with 0.09% of people taking chloroquine and proguanil. Also a significantly higher number of
moderate neuropsychiatric symptoms occurred in mefloquine users compared with travellers who took chloroquine and proguanil. Steffen et
al found that 18.8% of travellers taking mefloquine had experienced side effects while 30.1% of the chloroquine and proguanil group reported problems.
Awareness: know about the risk of malaria
Bites by mosquitoes: prevent or avoid
Compliance: with appropriate drug regimen
Diagnosis: diagnose malaria swiftly and obtain treatment
promptly.
![]()
Incidence of side effects from prophylactic drugs
Top
Incidence of side effects from...
References

View larger version (27K):
[in a new window]
Number of cases of malaria, number of cases of falciparum
malaria, and number of deaths from malaria in the United Kingdom,
1977-97. Data supplied by the Malaria Reference Laboratory, London
School of Hygiene and Tropical Medicine (E Walker, personal
communication)
Commonly reported side effects of antimalaria drugs
Mefloquine
Chloroquine
Proguanil
Maloprim
Nausea
Nausea
Nausea
Agranulocytosis
Dizziness
Visual accommodation problems
Mouth ulcers
Neuropsychiatric problems (anxiety, depression, panic, hallucinations)
Corneal or retinal changes (after prolonged use)
![]()
References
Top
Incidence of side effects from...
References
© BMJ 1998
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+